These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 896840)

  • 1. Ethanol, levodopa and inhibitors of extracerebral aromatic L-amino acid decarboxylase: a drug-drug interaction study.
    Messiha FS
    Proc West Pharmacol Soc; 1977; 20():327-31. PubMed ID: 896840
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.
    Pinder RM; Brogden RN; Sawyer PR; Speight TM; Avery GS
    Drugs; 1976; 11(5):329-77. PubMed ID: 782834
    [No Abstract]   [Full Text] [Related]  

  • 3. Interactions of levodopa with inhibitors of monoamine oxidase and L-aromatic amino acid decarboxylase.
    Teychenne PF; Calne DB; Lewis PJ; Findley LJ
    Clin Pharmacol Ther; 1975 Sep; 18(3):273-7. PubMed ID: 1164817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of aromatic-L-amino acid decarboxylase by decarboxylase inhibitors in idiopathic parkinsonism.
    Boomsma F; Meerwaldt JD; Man in 't Veld AJ; Hovestadt A; Schalekamp MA
    Ann Neurol; 1989 Jun; 25(6):624-8. PubMed ID: 2742363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat.
    Jonkers N; Sarre S; Ebinger G; Michotte Y
    J Neural Transm (Vienna); 2001; 108(5):559-70. PubMed ID: 11459076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human and rat hepatic aminotransferase activity with L-3,4-dihydroxyphenylalanine by inhibitors of peripheral aromatic amino acid decarboxylase.
    Waterhouse MJ; Chia YC; Lees GJ
    Mol Pharmacol; 1979 Jan; 15(1):108-14. PubMed ID: 423884
    [No Abstract]   [Full Text] [Related]  

  • 7. Decarboxylase inhibitors.
    Bartholini G; Pletscher A
    Pharmacol Ther B; 1975; 1(3):407-21. PubMed ID: 772711
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on the mechanism of stimulation of dopamine synthesis by amphetamine in striatal slices.
    Uretsky NJ; Snodgrass SR
    J Pharmacol Exp Ther; 1977 Sep; 202(3):565-80. PubMed ID: 197227
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of some decarboxylase inhibitors on striatal tyramines in the mouse.
    Juorio AV
    Neuropharmacology; 1983 Jan; 22(1):71-3. PubMed ID: 6843786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase.
    Wilke WL
    Pediatr Res; 1983 Nov; 17(11):924-5. PubMed ID: 6359046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics.
    Dingemanse J; Kleinbloesem CH; Zürcher G; Wood ND; Crevoisier C
    Br J Clin Pharmacol; 1997 Jul; 44(1):41-8. PubMed ID: 9241095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J
    Med Ann Dist Columbia; 1974 Dec; 43(12):587-91. PubMed ID: 4532167
    [No Abstract]   [Full Text] [Related]  

  • 14. The action of L-dopa in rats with the raphe nuclei lesions.
    Maj J; Przewlocka B
    Pol J Pharmacol Pharm; 1975 Oct; 27(Suppl):151-4. PubMed ID: 1208224
    [No Abstract]   [Full Text] [Related]  

  • 15. Systemic and in vitro effects of GAD and GABA-T inhibitors on AADC activity and of AADC inhibitors on GAD.
    Giorgi O; Rubio MC
    Gen Pharmacol; 1981; 12(4):217-23. PubMed ID: 7250670
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of the effects of decarboxylase inhibitors on L-dopa-induced circling behavior and the conversion of dopa to dopamine in the brain.
    Goodale DB; Moore KE
    Life Sci; 1976 Sep; 19(5):701-6. PubMed ID: 957902
    [No Abstract]   [Full Text] [Related]  

  • 17. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N; Kuzuya F; Mori K; Sakamoto N
    Nihon Ronen Igakkai Zasshi; 1978 Nov; 15(6):566-73. PubMed ID: 732010
    [No Abstract]   [Full Text] [Related]  

  • 18. A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats.
    Grange S; Holford NH; Guentert TW
    Pharm Res; 2001 Aug; 18(8):1174-84. PubMed ID: 11587490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats.
    Chang WY; Webster RA
    Br J Pharmacol; 1997 May; 121(2):331-7. PubMed ID: 9154345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
    Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y
    Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.